Lymphoma & Myeloma 2010

 
 
 

Lymphoma & Myeloma 2010: An International Congress on Hematologic Malignancies took place October 21-23, 2010, in New York, New York.

 

Updates on zoledronic acid research

Mark Fuerst Read Article
Published: 11/18/10

 Gareth Morgan, MD
Gareth Morgan, MD

Zoledronic acid exerts both direct and indirect anti-myeloma effects in the treatment of newly diagnosed multiple myeloma (MM) patients, according to the results of the first large, randomized trial to show that one bisphosphonate is superior to another for the prevention of skeletal-related events (SRE). The MRC Myeloma IX Trial shows that zoledronic acid reduces the risk of SREs, increases progression-free survival (PFS), and overall survival (OS) compared to clodronate in multiple myeloma, reported Gareth Morgan, MD, at Lymphoma & Myeloma 2010. [Read Article]

Is surveillance imaging in DLBCL worth it?

Mark Fuerst Read Article
Published: 11/09/10

PET scans
PET scans

Surveillance imaging in diffuse large B-cell lymphoma (DLBCL) is of unclear utility and is associated with high costs and patient anxiety, said Rebecca Elstrom, MD, of Weill Cornell Medical College in New York at Lymphoma & Myeloma 2010. Dr Elstrom also said that while PET/CT is useful in staging and post-treatment response assessment, there is no current role for PET in surveillance, except in specific circumstances. [Read Article]

Tumor microenvironment affects lymphoma pathogenesis and treatment

Mark Fuerst Read Article
Published: 11/08/10

DLBCL cells
DLBCL cells

Immune cells can be used to predict survival of follicular lymphoma patients just as the stromal signature can used to predict survival in diffuse large B-cell lymphoma (DLBCL), said Jia Ruan, MD, PhD, of Weill-Cornell Medical College in New York at Lymphoma & Myeloma 2010. Patients with follicular lymphoma may survive for periods of less than 1 year to more than 20 years after diagnosis. Infiltrating immune cells can help predict survival. [Read Article]

IHC profile predicts response in DLBCL

Mark Fuerst Read Article
Published: 11/02/10

DLBCL cells
DLBCL cells

The immunohistochemical (IHC) profile has emerged as a potential prognostic and predictive factor in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy. However, the prognostic role of the IHC profile in these patients has not been completely elucidated, said Jorge J. Castillo, MD, of Miriam Hospital in Providence, Rhode Island, at Lymphoma & Myeloma 2010, held in New York, New York. [Read Article]

Early Hodgkin lymphoma patients may not need radiation

Mark Fuerst Read Article
Published: 10/29/10

Hodgkin’s lymphoma cells
Hodgkin lymphoma cells

Radiation therapy may be an anachronism in Hodgkin lymphoma, said George Canellos, MD, of Dana-Farber Cancer Institute in Boston, who made the case for chemotherapy alone treatments in early disease at Lymphoma & Myeloma 2010. Treating localized Hodgkin lymphoma with combined modalities has led to improved freedom from progression, limited radiation fields, and obviated the need for laparotomy, said Dr Canellos. [Read Article]

Ofatumumab plus CHOP induces high RR in FL

Mark Fuerst Read Article
Published: 10/28/10

Multiple myeloma cells
Multiple myeloma cells

Ofatumumab combined with CHOP chemotherapy induces high response rates (RR) in previously untreated patients with follicular lymphoma (FL) across all risk groups, according to a presentation at Lymphoma & Myeloma 2010, held in New York, New York. Myron Czuczman, MD, of Roswell Park Cancer Institute in Buffalo, New York, reported results of an open-label, randomized, two-dose parallel-group phase 2 study that investigated ofatumumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone as a frontline treatment for patients with follicular lymphoma. [Read Article]

CR not necessarily the ultimate endpoint in MM treatment

Erilyn Riley Read Article
Published: 10/27/10

 Angela Dispenzieri, MD
Angela Dispenzieri, MD

With myeloma research and clinical trials moving at a rapid pace, physicians should be careful not to use response only as the ultimate endpoint in choosing treatment for their multiple myeloma (MM) patients, cautioned Angela Dispenzieri, MD, of the Mayo Clinic in Rochester, Minnesota. She discussed how staging, risk stratification, and response evaluations impact treatment choices during Lymphoma & Myeloma 2010 held recently in New York. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}